Hanmi Finds Global Poziotinib Partner In Spectrum
This article was originally published in PharmAsia News
Executive Summary
After a similar deal with China’s Luye in August last year, Hanmi is licensing out its cancer candidate poziotinib, this time to its existing partner Spectrum for most global markets, in an indication of the growing attractiveness of South Korean innovation.